Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival

European Journal of Cancer

Volumn 52, Issue , 2016, Pages 41-49

  Rossi, Marta ^a,b   Carioli, Greta ^b   Bonifazi, Martina ^a   Zambelli, Alberto ^c   Franchi, Matteo ^d   Moja, Lorenzo ^b,e   Zambon, Antonella ^d   Corrao, Giovanni ^d   La Vecchia, Carlo ^b   Zocchetti, Carlo ^f   Negri, Eva ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^f Operative Unit of Territorial Health Services   (Italy)

Author keywords

Cardiotoxicity; Metastatic breast cancer; Survival; Trastuzumab

Indexed keywords

CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DATA BASE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; AGE; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; BREAST NEOPLASMS; CHEMICALLY INDUCED; ENZYMOLOGY; EPIDEMIOLOGY; FACTUAL DATABASE; HEART DISEASES; INCIDENCE; ITALY; KAPLAN MEIER METHOD; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; SECONDARY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; BREAST NEOPLASMS; DATABASES, FACTUAL; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; ITALY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84948394457     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.09.012     Document Type: Article

References (30)

1. J. Baselga, and J. Albanell Mechanism of action of anti-HER2 monoclonal antibodies Ann Oncol 12 Suppl. 1 2001 S35 S41
2. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, and et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 3 1996 737 744
3. M.A. Cobleigh, C.L. Vogel, D. Tripathy, N.J. Robert, S. Scholl, L. Fehrenbacher, and et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 9 1999 2639 2648
4. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 1987 177 182
5. Administration FaD HERCEPTIN (trastuzumab) Label-FDA 1998
6. S. Balduzzi, S. Mantarro, V. Guarneri, L. Tagliabue, V. Pistotti, L. Moja, and et al. Trastuzumab-containing regimens for metastatic breast cancer Cochrane Database Syst Rev 6 2014 CD006242
7. S.A. Crone, Y.Y. Zhao, L. Fan, Y. Gu, S. Minamisawa, Y. Liu, and et al. ErbB2 is essential in the prevention of dilated cardiomyopathy Nat Med 8 5 2002 459 465
8. Y.Y. Zhao, D.R. Sawyer, R.R. Baliga, D.J. Opel, X. Han, M.A. Marchionni, and et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes J Biol Chem 273 17 1998 10261 10269
9. S. Golder, Y.K. Loke, and M. Bland Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview PLoS Med 8 5 2011 e1001026
10. M. Bonifazi, M. Franchi, M. Rossi, A. Zambelli, L. Moja, A. Zambon, and et al. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice Breast 23 5 2014 573 578
11. M. Bonifazi, M. Franchi, M. Rossi, L. Moja, A. Zambelli, A. Zambon, and et al. Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study Oncologist 18 7 2013 795 801
12. G. Corrao, A. Parodi, F. Nicotra, A. Zambon, L. Merlino, G. Cesana, and et al. Better compliance to antihypertensive medications reduces cardiovascular risk J Hypertens 29 3 2011 610 618
13. G. Corrao, S.A. Romio, A. Zambon, L. Merlino, E. Bosi, and M. Scavini Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy Eur J Clin Pharmacol 67 3 2011 289 299
14. G. Corrao, L. Scotti, A. Zambon, G. Baio, F. Nicotra, V. Conti, and et al. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases Atherosclerosis 217 2 2011 479 485
15. R.L. Prentice, J.D. Kalbfleisch, A.V. Peterson Jr., N. Flournoy, V.T. Farewell, and N.E. Breslow The analysis of failure times in the presence of competing risks Biometrics 34 4 1978 541 554
16. J. Fine, and R. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
17. A. Esposito, E. Munzone, V. Bagnardi, L. Adamoli, A. Sciandivasci, D. Cullura, and et al. Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients? Anticancer Drugs 23 10 2012 1089 1098
18. P.A. Kaufman, A.M. Brufsky, M. Mayer, H.S. Rugo, D. Tripathy, M.U. Yood, and et al. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study Breast Cancer Res Treat 135 3 2012 875 883
19. C. Serrano, J. Cortes, L. De Mattos-Arruda, M. Bellet, P. Gomez, C. Saura, and et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors Ann Oncol 23 4 2012 897 902
20. B. Kaufman, J.R. Mackey, M.R. Clemens, P.P. Bapsy, A. Vaid, A. Wardley, and et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 33 2009 5529 5537
21. M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, and et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 19 2005 4265 4274
22. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, and et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 2001 783 792
23. G. von Minckwitz, A. du Bois, M. Schmidt, N. Maass, T. Cufer, F.E. de Jongh, and et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study J Clin Oncol 27 12 2009 1999 2006
24. D.B. Sawyer, C. Zuppinger, T.A. Miller, H.M. Eppenberger, and T.M. Suter Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity Circulation 105 13 2002 1551 1554
25. Y.X. Shi, Y.T. Tan, Z.Y. Yuan, S.S. Wang, R.J. Peng, X. An, and et al. Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer Med Oncol 29 1 2012 39 47
26. J.M. Extra, E.C. Antoine, A. Vincent-Salomon, T. Delozier, P. Kerbrat, A. Bethune-Volters, and et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study Oncologist 15 8 2010 799 809
27. F. Montemurro, M. Donadio, M. Clavarezza, S. Redana, M.E. Jacomuzzi, G. Valabrega, and et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy Oncologist 11 4 2006 318 324
28. D. Tripathy, P.A. Kaufman, A.M. Brufsky, M. Mayer, M.U. Yood, B. Yoo, and et al. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER Oncologist 18 5 2013 501 510
29. E. Negri, A. Zambelli, M. Franchi, M. Rossi, M. Bonifazi, G. Corrao, and et al. Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a Controlled Cohort Study Oncologist 19 12 2014 1209 1215
30. M. Bonifazi, M. Rossi, L. Moja, V.D. Scigliano, M. Franchi, C. La Vecchia, and et al. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety Oncologist 17 1 2012 117 124